We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Multiplex Vaginal Panel Identifies Three Distinct Conditions in One Hour

By LabMedica International staff writers
Posted on 22 Nov 2022

Each year, about 10 million healthcare visits by women in the U. More...

S. are related to vaginitis symptoms. Diagnosis of vaginitis is often made through a clinical examination where the physician will prescribe a treatment regimen that may not be targeted to the patients' specific infection type. Sequential treatment failures prolong patient suffering and increase the potential for antimicrobial resistance. Since the causative agents are from three distinct pathogen classes, but present with similar symptoms, a precise diagnosis afforded by multiplexed PCR testing can enable more targeted and timely treatments. Bacterial vaginosis (BV) is the most common cause of the vaginitis/vaginosis syndrome, but vaginitis can also be caused by Trichomonas and yeasts such as Candida. Antibiotic use is a major factor responsible for Candida overgrowth, so identifying the underlying infection is critical to decrease the overuse of antibiotics. The rate of BV recurrence after therapy is high, often greater than 60%, and compared to a molecular test, empiric approaches can miss 45.3% of positive cases and incorrectly identify 12.3% of negative cases as positives.

Now, a new multiplexed PCR test detects DNA from organisms associated with three distinct conditions – BV, vulvovaginal candidiasis, and trichomoniasis – from a single sample, aiding in more accurate diagnosis and antibiotic treatment regimens. Cepheid (Sunnyvale, CA, USA) has launched Xpert Xpress MVP which aids clinicians in the detection of these infections, including co-occurrences from a single sample with a detection time within 60 minutes, significantly narrowing the test-to-treatment gap and better supporting patient outcomes.

"Misdiagnosis of the specific underlying causes of vaginitis and vaginosis often lead to inappropriate and ineffective treatments and, in some cases, an increased risk of developing serious complications and antibiotic resistant organisms," said David Persing, M.D., Ph.D., EVP, and Chief Scientific Officer. "With the addition of the MVP to our growing women's health portfolio, physicians can quickly and accurately identify their patient's infection and prescribe the correct treatment regimen, with the goal of avoiding multiple office visits associated with therapeutic failure."

Related Links:
Cepheid


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.